Myocardial infarction in rats: effects of metabolic and pharmacologic interventions.
Myocardial infarction was induced in rats by ligation of the descending branch of the left coronary artery. The time course of changes in heart function was recorded within the first nine days. There was a progressive decline in LVSP, in LV dP/dtmax and in the pressure-rate-product. LVEDP was elevated. Cardiac output and stroke volume index were depressed after two days. The ATP content in the nonischemic region was lower than control, but recovered spontaneously toward the normal value within the first four days. Three metabolic and pharmacologic interventions known to affect cardiac adenine nucleotide metabolism were applied. Continuous i.v. administration of ribose which stimulates further adenine nucleotide biosynthesis attenuated the fall and promoted the restoration of ATP in the nonischemic myocardium within four days after coronary artery ligation. The elevation of LVEDP was attenuated with ribose after two and four days. The calcium antagonist gallopamil administered as i.v. infusion for two days led to a further reduction of all parameters of left heart function, but did not influence the increase in adenine nucleotide and protein synthesis that occurred in the nonischemic heart. Coenzyme Q10 had only slight effects on LVSP, LVEDP, and LV dP/dtmax, but attenuated significantly the fall in cardiac output and stroke volume index after two days following coronary artery ligation. Thus, all interventions affected differently the infarct-induced changes in heart and circulatory function. An improvement was observed with ribose and with coenzyme Q10.
Zimmer
H G
HG
Physiologisches Institut, Universität München, FRG.
Martius
P A
PA
Marschner
G
G
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D003067:Coenzymes; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D005711:Gallopamil / Q000008:administration & dosage*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D007262:Infusions, Intravenous; D009203:Myocardial Infarction / Q000628:therapy*; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D012266:Ribose / Q000008:administration & dosage*; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives*
D003067:Coenzymes; D014451:Ubiquinone; D005711:Gallopamil; D012266:Ribose; D000255:Adenosine Triphosphate; C024989:coenzyme Q10